Matches in SemOpenAlex for { <https://semopenalex.org/work/W47486919> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W47486919 endingPage "21" @default.
- W47486919 startingPage "12" @default.
- W47486919 abstract "Evidence has been accrued recently that chronic high levels of asymmetric dimethylarginine (ADMA) can be directly beneficial to the treatment of atherosclerotic vascular disorders thus making the substance a promising new therapeutic target. A therapeutic target can be theoretically each stage in the process of generation and elimination of asymmetric dimethylarginine. The methylation of L-arginine residues is a universal biological process involving hundreds of proteins but still with unknown effects. Interference with these mechanisms can generate ambiguous and speculative discussions. Supplementation with L-arginine seems to be the most natural way to reverse the detrimental effect of ADMA on the endothelium. The enzymatic activity of endogenous nitric oxide synthase is regulated by the ratio between the concentrations of L-arginine (the natural substrate) and that of ADMA (the endogenous inhibitor): in the presence of normal L-arginine levels, any elevation ofADMA levels may cause relative L-arginine deficiency thus attenuating the activity of the endogenous nitric oxide synthase. Target replacement therapy with L-arginine to increase the L-arginine plasma levels results in the normalisation of the L-arginine/ADMA ratio in the presence of higher levels of the latter. There is still some controversy about the effects of the most frequently used drugs on asymmetric dimethylarginine. Most of the relevant studies show that statins do not affect the ADMA levels. On the other hand, patients with high levels of ADMA are resistant to statin therapy--to improve the endothelium-dependent vasodilation they need a combined therapy with L-arginine. The angiotensin-converting enzyme inhibitors and the angiotensin receptor blockers are the most extensively studied substances, the studies predominantly centring on confirming their ADMA reducing effect. Until the specific ADMA-reducing therapy becomes readily available, it is the therapies of modification of the risk factors causing the increase of ADMA or the depletion of L-arginine, and the L-arginine replacement therapy that are the most realistic therapeutic solutions for patients with high plasma levels of ADMA because the synthesis of nitric oxide correlates with the L-arginine/ADMA ratio. A study was conducted in the Surgery of Preventive Cardiology with the Clinic of Cardiology in Plovdiv which included 40 patients with pronounced hypercholesterolemia (HC)--it was found that a one-month therapy with 40 mg simvastatin did not change statistically significantly ADMA plasma levels in spite of the optimal lipid regulation." @default.
- W47486919 created "2016-06-24" @default.
- W47486919 creator A5054634860 @default.
- W47486919 date "2008-01-01" @default.
- W47486919 modified "2023-09-27" @default.
- W47486919 title "Asymmetric dimethylarginine--mechanisms and targets for therapeutic management." @default.
- W47486919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18543783" @default.
- W47486919 hasPublicationYear "2008" @default.
- W47486919 type Work @default.
- W47486919 sameAs 47486919 @default.
- W47486919 citedByCount "0" @default.
- W47486919 crossrefType "journal-article" @default.
- W47486919 hasAuthorship W47486919A5054634860 @default.
- W47486919 hasConcept C120770815 @default.
- W47486919 hasConcept C126322002 @default.
- W47486919 hasConcept C134018914 @default.
- W47486919 hasConcept C16613235 @default.
- W47486919 hasConcept C185592680 @default.
- W47486919 hasConcept C2776992346 @default.
- W47486919 hasConcept C2777468819 @default.
- W47486919 hasConcept C2777622882 @default.
- W47486919 hasConcept C2779129087 @default.
- W47486919 hasConcept C2779877776 @default.
- W47486919 hasConcept C515207424 @default.
- W47486919 hasConcept C519581460 @default.
- W47486919 hasConcept C55493867 @default.
- W47486919 hasConcept C71924100 @default.
- W47486919 hasConcept C98274493 @default.
- W47486919 hasConceptScore W47486919C120770815 @default.
- W47486919 hasConceptScore W47486919C126322002 @default.
- W47486919 hasConceptScore W47486919C134018914 @default.
- W47486919 hasConceptScore W47486919C16613235 @default.
- W47486919 hasConceptScore W47486919C185592680 @default.
- W47486919 hasConceptScore W47486919C2776992346 @default.
- W47486919 hasConceptScore W47486919C2777468819 @default.
- W47486919 hasConceptScore W47486919C2777622882 @default.
- W47486919 hasConceptScore W47486919C2779129087 @default.
- W47486919 hasConceptScore W47486919C2779877776 @default.
- W47486919 hasConceptScore W47486919C515207424 @default.
- W47486919 hasConceptScore W47486919C519581460 @default.
- W47486919 hasConceptScore W47486919C55493867 @default.
- W47486919 hasConceptScore W47486919C71924100 @default.
- W47486919 hasConceptScore W47486919C98274493 @default.
- W47486919 hasIssue "1" @default.
- W47486919 hasLocation W474869191 @default.
- W47486919 hasOpenAccess W47486919 @default.
- W47486919 hasPrimaryLocation W474869191 @default.
- W47486919 hasRelatedWork W103834307 @default.
- W47486919 hasRelatedWork W1595151029 @default.
- W47486919 hasRelatedWork W1963909514 @default.
- W47486919 hasRelatedWork W1973434106 @default.
- W47486919 hasRelatedWork W1992128957 @default.
- W47486919 hasRelatedWork W1995271132 @default.
- W47486919 hasRelatedWork W1998493567 @default.
- W47486919 hasRelatedWork W2072531665 @default.
- W47486919 hasRelatedWork W2083518460 @default.
- W47486919 hasRelatedWork W2104168812 @default.
- W47486919 hasRelatedWork W2112585103 @default.
- W47486919 hasRelatedWork W2115875498 @default.
- W47486919 hasRelatedWork W2148224759 @default.
- W47486919 hasRelatedWork W2188878731 @default.
- W47486919 hasRelatedWork W2310343622 @default.
- W47486919 hasRelatedWork W2404751804 @default.
- W47486919 hasRelatedWork W2414579149 @default.
- W47486919 hasRelatedWork W2529750268 @default.
- W47486919 hasRelatedWork W2810595608 @default.
- W47486919 hasRelatedWork W2062801753 @default.
- W47486919 hasVolume "50" @default.
- W47486919 isParatext "false" @default.
- W47486919 isRetracted "false" @default.
- W47486919 magId "47486919" @default.
- W47486919 workType "article" @default.